Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Medicina (B.Aires) ; 81(4): 645-648, ago. 2021. graf
Article in English | LILACS | ID: biblio-1346519

ABSTRACT

Abstract Hereditary angioedema (HAE) is a rare disease with an autosomal dominant heredity pattern, due to mutations in the gene encoding the C1 esterase inhibitor. The onset of symptoms usually occurs during childhood. Clinically, it is characterized by repeated episodes of angioedema that may affect the skin, abdomen and larynx/pharynx. The occurrence of attacks and their severity are unpredictable and can be fatal without the appropriate treatment. We present the case of an asymptomatic 65-year-old woman, with a history of three adult children diagnosed with HAE. Despite the high probabilities of being a carrier of the mutation, she had not been previously studied. Diagnosis of HAE in a family member would require screening of all at-risk relatives. Early diagnosis is essential to establish a correct and timely therapeutic strategy in order to reduce the morbidity and mortality associated with the disease.


Resumen El angioedema hereditario (HAE) es una enfermedad rara, con un patrón de herencia autosómico dominante, debida a mutaciones en el gen que codifica el inhibidor de la C1 esterasa. El inicio de los síntomas suele ocurrir durante la infancia. Clínicamente se caracteriza por episodios recurrentes de angioedema que pueden afectar la piel, el abdomen y la laringe/faringe. La ocurrencia de los ataques y su gravedad son imprevisibles, y puede resultar fatal sin el tratamiento apropiado. Presentamos el caso de una mujer de 65 años de edad, asintomática, con antecedente de tres hijos adultos con diagnóstico de HAE, quién pese a la alta probabilidad de ser portadora de la mutación, no había sido estudiada previamente. El diagnóstico de HAE en un integrante de la familia obligaría a realizar estudios de cribado en todos los familiares en riesgo. El diagnóstico temprano resulta fundamental para establecer una estrategia terapéutica correcta y oportuna, disminuyendo así la morbimortalidad asociada a la enfermedad.


Subject(s)
Humans , Female , Aged , Angioedemas, Hereditary/diagnosis , Angioedemas, Hereditary/genetics , Angioedema , Family , Complement C1 Inhibitor Protein , Mutation
2.
J. pediatr. (Rio J.) ; 97(supl.1): 10-16, Mar.-Apr. 2021. tab, graf
Article in English | LILACS | ID: biblio-1250226

ABSTRACT

Abstract Objectives: To describe the hereditary angioedema to improve awareness of this condition and reduce diagnostic delay. Data sources: Relevant articles in the MEDLINE database through PubMed. Data synthesis: Hereditary angioedema is rare and has an autosomal dominant pattern of inheritance. Its onset occurs mainly in childhood, but there is an important delay in the diagnosis. In the most frequent phenotype, there is a quantitative and/or functional deficiency in the C1esterase inhibitor protein, which regulates the activation of the complement, contact and fibrinolysis systems with greater formation of bradykinin, the main mediator of angioedema. There is a third type, the hereditary angioedema with a normal C1 inhibitor level, which is rare in children. Clinical manifestations are characterized by recurrent angioedema attacks, mainly in the extremities, abdomen and upper airways, which can progress to asphyxia and death. The main triggers are mechanical trauma, infections and stress. The diagnosis is attained by patient clinical picture and decreased serum levels of C4 and C1esterase inhibitor or its function. In hereditary angioedema with a normal C1 inhibitor, there is no change in these parameters, thus requiring a genetic study. Treatment is based on the use of attack medications and long and short-term prophylaxis. Conclusions: Hereditary angioedema is little known by pediatricians due to the significant delay in diagnosis of this condition, whose onset usually begins in childhood. The presence of recurrent angioedema that does not respond to treatment with antihistamines, corticosteroids and adrenaline should increase the diagnostic suspicion.


Subject(s)
Humans , Child , Angioedemas, Hereditary/diagnosis , Angioedemas, Hereditary/genetics , Angioedema , Bradykinin , Delayed Diagnosis , Pediatricians
3.
Rev Assoc Med Bras (1992) ; 66(4): 502-506, 2020. tab, graf
Article in English | SES-SP, LILACS | ID: biblio-1136216

ABSTRACT

SUMMARY OBJECTIVE To investigate the presence of the Angiopoietin 1 (ANGPT1) and Plasminogen (PLG) mutations in patients with Hereditary Angioedema (HAE) and normal C1 esterase inhibitor (C1-INH) levels, who do not harbor the F12 gene mutation. METHODS Patients clinically diagnosed with HAE but without C1-INH deficiency or dysfunction and F12 gene mutation were evaluated. DNA extraction, quantification, and dilution were performed at a concentration of 100 ng/µL, followed by a DNA amplification (PCR) for molecular evaluation of exon 2 of the ANGPT1 gene and exon 9 of the PLG gene for identification of mutations c.807G>T / p.A119S and c.988A>G / p.K330E, respectively. The PCR product was evaluated in 1% agarose gel electrophoresis. Sequencing was performed using the Sanger method. The electropherograms were analyzed using the FASTA® program. RESULTS DNA samples from 15 women were sequenced. Their ages ranged from 10 to 60 years and the normal C1 esterase and C4 inhibitor serum levels ranged from 22 to 39 mg/dL and from 10 to 40 mg/dL, respectively. No mutations were detected in the analyzed exons of ANGPT1 and PLG. However, a single-nucleotide polymorphism (SNP) was detected in two homozygotic and five heterozygotic patients. CONCLUSION Further studies are needed to evaluate these SNPs and scrutinize their potential for use as molecular markers of HAE and as novel therapeutic targets.


RESUMO OBJETIVO Investigar a presença das mutações no gene Angiopoietina (ANGPT1) e gene Plasminogênio (PLG) em pacientes com Angioedema Hereditário (AEH) com inibidor C1 esterase (C1-INH) normal e negativos para mutação do gene F12. MÉTODOS Foram avaliados pacientes com diagnóstico clínico de AEH sem deficiência ou disfunção de C1-INH e negativos para mutação do gene F12. Realizou-se extração, quantificação e diluição do DNA a uma concentração de 100 ng/uL, em seguida amplificação do DNA (PCR) para avaliação molecular do exon 2 do gene ANGPT1 e do exon 9 do gene PLG para identificação das mutações c.807G>T.p.A119S e c.988A>G p.K330E, respectivamente. O produto da PCR foi avaliado em eletroforese em gel de agarose 1%. Foi realizado o sequenciamento pelo método de Sanger. As análises dos eletroferogramas foram realizadas pelo programa FASTA®. RESULTADOS Foram sequenciadas amostras de 15 mulheres, idade entre 10 e 60 anos, com níveis séricos de inibidor de C1 esterase e C4 normais variando de 22 a 39mg/dL e 10 a 40mg/dL, respectivamente. Não foram identificadas mutações nos éxons analisados dos genes ANGPT1 e PLG. Entretanto no gene PLG foram encontrados polimorfismo de nucleotídeo único (SNP), em duas pacientes homozigotas e cinco heterozigotas. CONCLUSÃO Mais estudos sobre SNP são necessários para esclarecer estes achados pois eles podem ser utilizados como marcadores moleculares do AEH e alvo para novos tratamentos.


Subject(s)
Humans , Female , Child , Adolescent , Adult , Young Adult , Plasminogen/genetics , Angiopoietins/genetics , Angioedemas, Hereditary/genetics , Polymerase Chain Reaction , Complement C1 Inhibitor Protein , Middle Aged , Mutation
4.
S. Afr. med. j. (Online) ; 108(4): 283-290, 2018.
Article in English | AIM | ID: biblio-1271198

ABSTRACT

Background. Hereditary angio-oedema (HAE) is an autosomal dominant condition caused by a deficiency in the C1-esterase inhibitor protein, resulting in increased bradykinin release. It presents clinically with recurrent attacks of angio-oedema, commonly affecting the limbs, face, upper airway and gastrointestinal tract. Little is known about this condition in sub-Saharan Africa.Objectives. To analyse and report on the clinical presentation and treatment of patients with HAE in the Western Cape Province, South Africa.Methods. A retrospective analysis was conducted on a series of 60 cases of HAE seen between 2010 and 2015 at the Allergy Diagnostic and Clinical Research Unit, University of Cape Town Lung Institute, and the Allergy Clinic at Groote Schuur Hospital, Cape Town. The findings in 43 cases of type 1 HAE are described.Parameters assessed included age, gender, age of diagnosis, duration of illness, family history, identifiable triggers, average duration of attack, number of attacks per year and type of attack.Results. A total of 43 patients were included in this study. Of these, 65.1% (28/43) were female. The median age at diagnosis was 20 years (interquartile range (IQR) 10 - 27) and the median duration of illness 10.5 years (IQR 6 - 22). Of the patients, 62.8% (27/43), 32.6% (14/43) and 4.7% (2/43) were of mixed ancestry, white and black African, respectively; 51.2% (22/43) were index cases, with the remaining 48.8% (21/43) diagnoses via family member screening, 12 families making up the majority of the cohort. The mean (standard deviation) duration of an acute attack was 49 (25.8) hours, and 64.3% (27/42), 71.4% (30/42), 14.3% (6/42) and 88.1% (37/42) of patients experienced facial or upper airway, abdominal, external genitalia and limb attacks, respectively.Danazol for long-term prophylaxis was used in 21 patients, while C1-inhibitor concentrate (Berinert) was accessed for short-term prophylaxis in only four patients. Acute life-threating attacks were treated with fresh frozen plasma in 11 patients, and only four accessed icatibant. The mortality rate for the period 2010 - 2015 was 4.5% (2/43). The prevalence of HAE in the Western Cape was estimated to be 1:140 000.Conclusions.HAE occurs in South Africans of all ethnicities, and life-threatening attacks occur in almost two-thirds of patients. Despite limited therapeutic options and very limited access to gold-standard therapies available in the developed world, our mortality rate is very low, with both the deaths related to inability to access emergency treatment rapidly


Subject(s)
Angioedemas, Hereditary , Angioedemas, Hereditary/diagnosis , Angioedemas, Hereditary/genetics , South Africa
5.
An. bras. dermatol ; 92(5): 655-660, Sept.-Oct. 2017. tab, graf
Article in English | LILACS | ID: biblio-887019

ABSTRACT

Abstract: Background: Hereditary angioedema is a rare autosomal dominantly inherited immunodeficiency disorder characterized by potentially life-threatening angioedema attacks. Objective: We aimed to investigate the clinical and genetic features of a family with angioedema attacks. Methods: The medical history, clinical features and C1-INH gene mutation of a Turkish family were investigated and outcomes of long-term treatments were described. Results: Five members had experienced recurrent swellings on the face and extremities triggered by trauma. They were all misdiagnosed as familial Mediterranean fever (FMF) depending on frequent abdominal pain and were on colchicine therapy for a long time. They had low C4 and C1-INH protein concentrations and functions. A mutation (c.1247T>A) in C1-INH gene was detected. They were diagnosed as having hereditary angioedema with C1-INH deficiency (C1-INH hereditary angioedema) for the first time. Three of them benefited from danazol treatment without any significant adverse events and one received weekly C1 esterase replacement treatment instead of danazol since she had a medical history of thromboembolic stroke. Study limitations: Small sample size of participants. Conclusion: Patients with C1-INH hereditary angioedema may be misdiagnosed as having familial Mediterranean fever in regions where the disorder is endemic. Medical history, suspicion of hereditary angioedema and laboratory evaluations of patients and their family members lead the correct diagnoses of hereditary angioedema. Danazol and C1 replacement treatments provide significant reduction in hereditary angioedema attacks.


Subject(s)
Humans , Male , Female , Child , Adult , Middle Aged , Danazol/therapeutic use , Estrogen Antagonists/therapeutic use , Complement C1 Inhibitor Protein/genetics , Angioedemas, Hereditary/drug therapy , Pedigree , Time Factors , Turkey , Base Sequence , Gene Amplification , Treatment Outcome , Complement C1 Inhibitor Protein/therapeutic use , Angioedemas, Hereditary/diagnosis , Angioedemas, Hereditary/genetics , Mutation
6.
Arch. alerg. inmunol. clin ; 47(4): 146-151, 2016. ilus
Article in Spanish | LILACS | ID: biblio-915659

ABSTRACT

A pesar de que el angioedema hereditario es un padecimiento raro, tiene una amplia bibliografía que ratifica que la fisiopatología de esta enfermedad es compleja. La constante investigación de la industria farmacéutica no solo ha aportado nuevos recursos terapéuticos sino que ha logrado despertar un inusitado interés en la comunidad médica, permitiendo que tengamos una mayor comprensión sobre los mecanismos que presiden la aparición de las crisis. El Comité de Angioedema Hereditario de la AAAeIC ha desarrollado una puesta al día sobre esta entidad, que, por las características de sus síntomas, es abordada principalmente por los especialistas en alergia e inmunología clínica(AU)


Although hereditary angioedema is a rare condition, it has a large number of references that confirm that the pathophysiology of this disease is complex. The constant research of the pharmaceutical industry has not only brought new therapeutic resources, but also aroused an unusual interest in the medical community, allowing us to have a better understanding of the mechanisms that perform the onset of crises. The AAA e IC Hereditary Angioedema Committee has developed an update on this entity, which, due to the characteristics of its symptoms, is mainly addressed by specialists in allergy and clinical immunology.(AU)


Subject(s)
Humans , Female , Adult , Angioedemas, Hereditary/physiopathology , Angioedemas, Hereditary/genetics , Respiratory System , Skin , Bradykinin , Gastrointestinal Tract , Allergy and Immunology
7.
Mediciego ; 14(supl.1)mar. 2008.
Article in Spanish | LILACS | ID: lil-532331

ABSTRACT

El angiodema hereditario o familiar es una inmunodeficiencia primaria poco frecuente, es consecuencia de una deficiencia genética cuantitativa o cualitativa del C1-inhibidor que se transmite con carácter autosómico dominante, con penetrancia incompleta y alteración localizada en el cromosoma 11. La prevalencia de esta enfermedad se estima en 1:10-150.000 habitantes. Afecta a todas las razas y no tiene predominio por el sexo. La ausencia de historia familiar no descarta la posibilidad del diagnóstico, ya que el 15 por cientode los casos se deben a una mutación espontánea del gen. Existen tres formas clínicas: tipo I (85 por ciento), defecto de síntesis; tipo II (15 por ciento), síntesis de proteína disfuncional y tipo III, ligada al X con cantidades normales de C1-INH cuantitativa y cualitativamente. Su tratamiento resulta polémico por el gran número de aspectos inmunológicos involucrados. La importancia de un diagnóstico correcto nunca puede ser minimizada y es fundamental para evitar consecuencias potencialmente fatales tales como obstrucción de las vías respiratorias o cirugías abdominales innecesarias.


The hereditary or familiar angioedema is a primary inmunodeficiency not much frequent, is the consequence of a genetic deficiency quantitative or qualitative of C1-inhibidor that is trasmitted with dominant autosomal character, with incomplete penetrance and localized alteration in 11 chromosome. The prevalence of this disease is estimated in 1:10-150.000 inhabitants. It afects all races and doesn´t have dominance of sex. The absence of familiar history doesn´t eliminates the possibility of diagnosis, because the 15 percent ofthe cases are the result of a spontaneous mutation of the gene. There are three clinical ways: type I (85 percent), synthesis fault; type II (15 percent), synthesis of malfunctional protein and type III, linking to X with normal quantities qualitative and quantitative of C1-INH. Its treatment is polemic because of the great number of the involved inmunological aspects.The importance of an adequate diagnosis can be never minimized and is fundamental to avoid fatal consequences such as obstruction of the air passages or innecessary abdominal surgeries.


Subject(s)
Humans , Angioedemas, Hereditary/genetics
8.
Asian Pac J Allergy Immunol ; 2007 Jun-Sep; 25(2-3): 163-7
Article in English | IMSEAR | ID: sea-37202

ABSTRACT

Hereditary angioedema (HAE) is an autosomal dominant disorder caused by a deficiency of C1 esterase inhibitor (C1-INH). Affected individuals have attacks of swelling involving almost any part of the body. We studied a family with 15 living members, including a 16-year-old girl who had 3 attacks of angioedema in 2 years. Her paternal uncle had died of asphyxiation during an attack 15 years previously. We analyzed the blood of each family member for C3, C4, and C1-INH levels and sequenced the SERPING1 (formerly C1NH) gene that codes for C1-INH. Six individuals had decreased serum levels of C4 and C1-INH, and they were all found to have a single nucleotide A deletion at codon 210 of the gene, 1210fsX210, a novel mutation that accounts for the HAE in this family.


Subject(s)
Acute Disease , Adolescent , Angioedemas, Hereditary/genetics , Base Sequence , Complement C1 Inactivator Proteins/genetics , Complement C4/analysis , Complement System Proteins/analysis , Female , Humans , Male , Molecular Sequence Data , Mutation , Pedigree , Serpins/blood , Taiwan
SELECTION OF CITATIONS
SEARCH DETAIL